Li J, Chen R, Cao L, Liu Y, Zhang Y, Wei X
Front Immunol. 2024; 15:1408969.
PMID: 39575255
PMC: 11578944.
DOI: 10.3389/fimmu.2024.1408969.
Liao K, Cheng J, Hu Y, Zhang B, Huang P, Liu J
Cancer Med. 2024; 13(19):e70202.
PMID: 39377592
PMC: 11459677.
DOI: 10.1002/cam4.70202.
Chong E, Kumashie K, Chong E, Fabrizio J, Gupta A, Svoboda J
J Infect Dis. 2024; 230(1):15-27.
PMID: 39052709
PMC: 11272091.
DOI: 10.1093/infdis/jiae106.
Kontandreopoulou C, Solomou E, Kolorizos E, Diamantopoulos P
Ann Hematol. 2024; 103(12):4971-4980.
PMID: 39008060
DOI: 10.1007/s00277-024-05869-8.
Parker R, Le J, Villa M, Luong A, Lin T, Lee Y
Int J Cancer. 2024; 155(12):2190-2200.
PMID: 39005114
PMC: 11499007.
DOI: 10.1002/ijc.35096.
Real-World Assessment of Recommended COVID-19 Vaccination Waiting Period after Chemotherapy.
Cheng K, Yen C, Chang R, Cheng-Chung Wei J, Wang S
Vaccines (Basel). 2024; 12(6).
PMID: 38932407
PMC: 11209144.
DOI: 10.3390/vaccines12060678.
Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland.
Macdonald C, Palmateer N, McAuley A, Lindsay L, Hasan T, Hameed S
NPJ Vaccines. 2024; 9(1):107.
PMID: 38877008
PMC: 11178861.
DOI: 10.1038/s41541-024-00898-w.
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.
Ripoll J, Tulledge-Scheitel S, Stephenson A, Ford S, Pike M, Gorman E
mBio. 2024; 15(5):e0040024.
PMID: 38602414
PMC: 11078006.
DOI: 10.1128/mbio.00400-24.
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era-A Study of KroHem, the Croatian Group for Hematologic Diseases.
Aurer I, Jaksic O, Basic-Kinda S, Mrdenovic S, Ostojic-Kolonic S, Lozic D
Biomedicines. 2024; 12(2).
PMID: 38397933
PMC: 10887065.
DOI: 10.3390/biomedicines12020331.
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.
Dukes C, Potez M, Lancet J, Kuter B, Whiting J, Mo Q
Vaccines (Basel). 2024; 12(1).
PMID: 38250826
PMC: 10818923.
DOI: 10.3390/vaccines12010013.
Outcomes of COVID-19 in patients with lymphomas participating in registered clinical trials: A real-world study from China in the Omicron outbreak era.
Sun P, Yang H, Zhao B, Wang Y, Nie M, Huang K
Cancer Med. 2023; 12(23):21148-21158.
PMID: 38011015
PMC: 10726839.
DOI: 10.1002/cam4.6678.
Retrospective Analysis of a Real-Life Use of Tixagevimab-Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19.
Capoluongo N, Mascolo A, Bernardi F, Sarno M, Mattera V, Di Flumeri G
Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895964
PMC: 10609705.
DOI: 10.3390/ph16101493.
COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?.
Harel R, Itchaki G
Acta Haematol. 2023; 147(1):60-72.
PMID: 37820599
PMC: 11251671.
DOI: 10.1159/000534540.
Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment.
Donhauser L, Veloso de Oliveira J, Schick C, Manlik W, Styblova S, Lutzenberger S
J Immunother Cancer. 2023; 11(9).
PMID: 37730271
PMC: 10510941.
DOI: 10.1136/jitc-2023-007387.
Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.
Reynolds G, Hall V, Teh B
Transpl Infect Dis. 2023; 25 Suppl 1:e14109.
PMID: 37515788
PMC: 10909447.
DOI: 10.1111/tid.14109.
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
Angotzi F, Petrella M, Berno T, Binotto G, Bonetto G, Branca A
Front Oncol. 2023; 13:1212752.
PMID: 37427126
PMC: 10324575.
DOI: 10.3389/fonc.2023.1212752.
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.
Meejun T, Srisurapanont K, Manothummetha K, Thongkam A, Mejun N, Chuleerarux N
Blood Adv. 2023; 7(18):5624-5636.
PMID: 37389818
PMC: 10514108.
DOI: 10.1182/bloodadvances.2023010349.
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
Qin K, Honjo K, Sherrill-Mix S, Liu W, Stoltz R, Oman A
PLoS Med. 2023; 20(6):e1004157.
PMID: 37384638
PMC: 10309642.
DOI: 10.1371/journal.pmed.1004157.
Long COVID treated successfully with antivirals in a rituximab-treated follicular lymphoma patient with persistent negative-antibodies to SARS-CoV2.
Tayar E, Isber R, Isber N
Heliyon. 2023; 9(6):e17149.
PMID: 37378376
PMC: 10284434.
DOI: 10.1016/j.heliyon.2023.e17149.
Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.
Giuliano A, Kuter B, Pilon-Thomas S, Whiting J, Mo Q, Leav B
Cancer Commun (Lond). 2023; 43(7):749-764.
PMID: 37377402
PMC: 10354405.
DOI: 10.1002/cac2.12453.
